logo
Loretta Swit, Emmy-winner who played Houlihan on pioneering TV series ‘M.A.S.H.,' has died at 87

Loretta Swit, Emmy-winner who played Houlihan on pioneering TV series ‘M.A.S.H.,' has died at 87

CNN5 days ago

Loretta Swit, who won two Emmy Awards playing Major Margaret Houlihan, the demanding head nurse of a behind-the-lines surgical unit during the Korean War on the pioneering hit TV series 'M.A.S.H.,' has died. She was 87.
Publicist Harlan Boll said Swit died Friday at her home in New York City, likely from natural causes.
Swit and Alan Alda were the longest-serving cast members on 'M.A.S.H.,' which was based on Robert Altman's 1970 film, which was itself based on a novel by Richard Hooker, the pseudonym of H. Richard Hornberger.
The CBS show aired for 11 years from 1972 to 1983, revolving around life at the 4077th Mobile Army Surgical Hospital, which gave the show its name. The two-and-a-half-hour finale on Feb. 28, 1983, lured over 100 million viewers, the most-watched episode of any scripted series ever.
Rolling Stone magazine put 'M.A.S.H.' at No. 25 of the best TV shows of all time, while Time Out put it at No. 34. It won the Impact Award at the 2009 TV Land annual awards. It won a Peabody Award in 1975 'for the depth of its humor and the manner in which comedy is used to lift the spirit and, as well, to offer a profound statement on the nature of war.'
In Altman's 1970 film, Houlihan was a one-dimensional character – a sex-crazed bimbo who earned the nickname 'Hot Lips.' Her intimate moments were broadcast to the entire camp after somebody planted a microphone under her bed.
Sally Kellerman played Houlihan in the movie version and Swit took it over for TV, eventually deepening and creating her into a much fuller character. The sexual appetite was played down and she wasn't even called 'Hot Lips' in the later years.
The growing awareness of feminism in the '70s spurred Houlihan's transformation from caricature to real person, but a lot of the change was due to Swit's influence on the scriptwriters.
'Around the second or third year I decided to try to play her as a real person, in an intelligent fashion, even if it meant hurting the jokes,' Swit told Suzy Kalter, author of 'The Complete Book of 'M.A.S.H.''
'To oversimplify it, I took each traumatic change that happened in her life and kept it. I didn't go into the next episode as if it were a different character in a different play. She was a character in constant flux; she never stopped developing.'
'M.A.S.H.' wasn't an instant hit. It finished its first season in 46th place, out of 75 network TV series, but it nabbed nine Emmy nominations. It was rewarded with a better time slot for its sophomore season, paired on Saturday nights with 'All in the Family,' then TV's highest-rated show. At the 1974 Emmys, it was crowned best comedy, with Alda winning as best comedy actor.
The series also survived despite cast churn. In addition to Swit and Alda, the first season featured Wayne Rogers, McLean Stevenson, Larry Linville and Gary Burghoff. Harry Morgan, Mike Farrell and David Ogden Stiers would later be added, while Jamie Farr and William Christopher had expanded roles.
Swit appeared in all but 11 episodes of the series, nearly four times longer than the Korean War itself, exploring issues like PTSD, sexism and racism. Swit pushed for a better representation for women.
'One of the things I liked, with Loretta's prodding, was every time I had a chance to write for her character, we'd get away from the Hot Lips angle and find out more about who Margaret was. She became more of a real person,' Alda told The Hollywood Reporter in 2018.
The series ended on a happy note for Houlihan, who spends much of the finale debating whether she wants to head to Tokyo or Belgium for her next overseas post. Ultimately she opts to return to America and work at a hospital, citing her father – a career Army man.
Swit didn't personally agree that was the correct decision for a military-minded official: 'I didn't think that was correct for my Margaret,' she told Yahoo Entertainment in 2023. 'I think her next move was Vietnam. So I didn't agree with that, but that's what they wanted her to do.'
But the actor did get to write the speech that Houlihan delivers to her fellow nurses on their final night together, in which she says: 'It's been an honor and privilege to have worked with you. And I'm very, very proud to have known you.'
'I was consumed with writing that. And I still get letters from women all over the world who became nurses because of Margaret Houlihan. To have contributed to someone's life like that is remarkable,' she told Yahoo Entertainment.
During her run, Houlihan had an affair with Hawkeye's foil, the bumbling Frank Burns, played by Linville in the TV version, and in Season 5, Houlihan returns from a stay in Tokyo engaged to a handsome lieutenant colonel, a storyline that Swit says she advocated for with the writers.
'I told them: 'Can you imagine what fun you're going to have with Larry when I come back to town and I tell him I'm engaged? He'll rip the doors off of the mess tent!' And that's exactly what they had him do. So we were all of the same mind.'
Toward the end, Swit was tempted to leave the show. She played the role of Chris Cagney in a 1981 television movie, 'Cagney & Lacey,' and was offered the part when it was picked up as a mid-season series for the spring of 1982. But producers insisted she stay with 'M.A.S.H.' for its last two seasons.
Swit told The Florida Times-Union in 2010 she might have stayed with 'M.A.S.H.' anyway. 'You can't help but get better as an actor working with scripts like that,' she said. 'If you're in something that literate, well, we got spoiled.'
In 2022, James Poniewozik, The New York Times's chief television critic, looked back on the show and said it held up well: 'Its blend of madcap comedy and pitch-dark drama – the laughs amplifying the serious stakes, and vice versa – is recognizable in today's dramedies, from 'Better Things' to 'Barry,' that work in the DMZ between laughter and sadness.'
After the TV series, Swit became a vocal animal welfare activist, selling SwitHeart perfume and her memoir through her official website, with proceeds benefiting various animal-related nonprofit groups.
In 1983, she married actor Dennis Holahan, whom she'd met when he was a guest star on 'M.A.S.H.' They divorced in 1995.
Born in Passaic, New Jersey, the daughter of Polish immigrants, Swit enrolled in the American Academy of Dramatic Arts, then paid her dues for years in touring productions.
In 1969, she arrived in Hollywood and was soon seen in series such as 'Gunsmoke,' 'Hawaii Five-O,' 'Mission Impossible' and 'Bonanza.' Then in 1972, she got her big break when she was asked to audition for the role of 'Hot Lips.'
She would regularly return to theater, starring on Broadway in 1975 in 'Same Time, Next Year' and 'The Mystery of Edwin Drood' in 1986. She was in 'Amorous Crossing,' a romantic comedy, at Alhambra Theatre & Dining in 2010 and in North Carolina Theatre's production of 'Mame' in 2003.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Restructuring Lawyers Kyle Ortiz and Brian Shaughnessy Join Herbert Smith Freehills Kramer in New York
Top Restructuring Lawyers Kyle Ortiz and Brian Shaughnessy Join Herbert Smith Freehills Kramer in New York

Associated Press

timean hour ago

  • Associated Press

Top Restructuring Lawyers Kyle Ortiz and Brian Shaughnessy Join Herbert Smith Freehills Kramer in New York

NEW YORK--(BUSINESS WIRE)--Jun 4, 2025-- Herbert Smith Freehills Kramer announced today that leading restructuring attorneys Kyle J. Ortiz and Brian F. Shaughnessy have joined the firm as partners in its Bankruptcy and Restructuring Group. Ortiz and Shaughnessy advise debtors, creditors, and other parties in interest in complex restructurings both in and out of court. On June 1, 2025, Kramer Levin officially combined with Herbert Smith Freehills to become Herbert Smith Freehills Kramer, known as HSF Kramer. Ortiz has represented debtors and creditors in some of the largest and most complex chapter 11 cases of the past fifteen years including Eletson Holdings, LATAM Airlines, Greensill Capital, Pacific Drilling, Westinghouse, SunEdison, American Airlines, and Lehman Brothers. He has also represented investors and other creditors in complex restructuring matters, including cross-border restructurings. An experienced trial lawyer, Shaughnessy has nearly two decades of experience in complex business disputes involving bankruptcy, securities and contract issues, as well as regulatory and corporate governance matters, among others. 'We are delighted to welcome Brian and Kyle as the first new hires of HSF Kramer,' said Justin D'Agostino, Global CEO of Herbert Smith Freehills Kramer. 'Kyle is a widely-respected and dynamic adviser. Their addition enhances the pre-eminence and depth of our restructuring team and fits squarely into our strategic plan.' 'Kyle and Brian's deep experience in high-stakes restructurings and distressed situations will be instrumental in helping clients navigate an uncertain economic landscape,' said Amy Caton and Ken Eckstein, HSF Kramer's Heads of Bankruptcy and Restructuring, US. 'Their insight, creativity, and commercial acumen are a perfect fit for our solutions-driven group.' Paul Schoeman, executive partner of the U.S. region for Herbert Smith Freehills Kramer, said: 'I'm thrilled that Kyle and Brian are joining our premier bankruptcy and restructuring practice. Their arrival underscores the commitment that we at HSF Kramer have to building on our strengths and attracting top-level talent in key markets.' Ortiz added, 'I have consistently enjoyed working with and across from Kramer Levin's world-class restructuring team. I'm incredibly excited to join this team and to take advantage of the global reach and industry expertise that the HSF Kramer platform now has to offer.' Ortiz received his J.D. from The University of Chicago Law School and his B.A. from Northern Michigan University. Shaughnessy earned his J.D. from Georgetown University Law Center and his B.A., cum laude, from Harvard College. About Herbert Smith Freehills Kramer Herbert Smith Freehills Kramer (HSF Kramer) was formed in June 2025 through the transformational combination of Herbert Smith Freehills and Kramer Levin, creating a world-leading global law firm. With over 6,000 people including c.2,700 lawyers and spanning 26 offices, HSF Kramer provides comprehensive legal services across every major region of the world. Uniquely positioned to help clients achieve ambitious objectives, HSF Kramer delivers exceptional results in complex transactions and high-stakes disputes. For more information visit LinkedIn: View source version on CONTACT: Media contact: Jennifer Manton Tel: +1 212 715 7612 Email:[email protected] Christine Kiran Tel: +1 212-843-8364 Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL FINANCE SOURCE: Herbert Smith Freehills Kramer Copyright Business Wire 2025. PUB: 06/04/2025 10:12 AM/DISC: 06/04/2025 10:11 AM

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Yahoo

time2 hours ago

  • Yahoo

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by Sagimet's license partner, Ascletis Bioscience Co. Ltd., in China. Denifanstat is a once-daily oral small-molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for metabolic dysfunction-associated steatohepatitis (MASH) in the rest of the Sagimet recently initiated a Phase 1 first-in-human trial with a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. The trial randomized 480 patients in China to receive either denifanstat once daily or a placebo for 12 weeks. For the primary endpoint of treatment success, defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline at week 12, the denifanstat group demonstrated a statistically significant 33.2% rate over the placebo group's 14.6%. Additional goals further corroborated denifanstat's efficacy versus placebo, including: Reduction in total lesion count (57.4% vs 35.4%). Reduction in inflammatory lesion count (63.5% vs 43.2%). Reduction in non-inflammatory lesion count (51.9% vs. 28.9%). Ascletis reported that denifanstat was generally well-tolerated. Following 12 weeks of once-daily oral administration at 50 mg, treatment-emergent adverse events (TEAE) incidence rates were comparable between denifanstat and placebo. All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs. No deaths were reported. These Phase 3 results confirm that FASN inhibition represents a potential therapeutic approach within acne. Ascletis has indicated that it plans to submit denifanstat for approval to the China National Medical Products Administration. Building on Ascletis' Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. In other notable pharmaceutical industry news, GSK plc (NYSE:GSK) agreed to acquire Boston Pharmaceuticals' lead asset, efimosfermin alfa, a phase 3-ready, investigational specialty medicine for treating and preventing the progression of steatotic liver disease in May. Under the agreement, GSK will pay up to $2 billion in total cash consideration, including $1.2 billion upfront, with the potential for additional success-based milestone payments totaling $800 million. This highlights ongoing investment in the liver disease space, an area where Sagimet is also active with its MASH program. Price Action: SGMT stock is trading higher by 31.7% to $4.78 premarket at last check Wednesday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store